← brief for 2026-08-30 · Slowing decline

Impact of renal impairment on pharmacokinetics, safety, and tolerability of funobactam, combined with imipenem and cilastatin.

Key takeaways

A small safety study gave one dose of a new antibiotic to 48 people with normal, mild, moderate, severe kidney disease, or those on dialysis. The drug levels changed with kidney function — people on dialysis cleared it fastest. Dosing adjustments will be needed for those with poor kidney filtering rate (eGFR under 15).

Who did this work

Rodvold KA (University of Illinois Chicago, Chicago, Illinois, USA.) · Mamikonyan G (Clinartis LLC, Hollywood, Florida, USA.) · Wang Y (Evopoint Biosciences Co Ltd, Suzhou, China.) · McRoberts A (Pharmaron Germantown, Germantown, Maryland, USA.) · Garg D (Clinical Research Services Inc., Boynton Beach, Florida, USA.) · Preston R (Division of Clinical Pharmacology, University of Miami, Miami, Florida, USA.) · Marabury T (Orlando Clinical Research Center, Orlando, Florida, USA.) · Le M (Evopoint Biosciences Co Ltd, Suzhou, China.) · Li J (Evopoint Biosceinces USA, Inc., Concord, Massachusetts, USA.)

Source

Paper · Europe PMC, CKD · 2026-08-27
https://doi.org/10.1128/aac.00808-26